- Home
- NVO
NVO
Novo Nordisk A/S
as 10-07-2025 3:28pm EST
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
| Founded: | 1923 | Country: | Denmark |
| Employees: | N/A | City: | N/A |
| Market Cap: | 278.0B | IPO Year: | N/A |
| Target Price: | $82.20 | AVG Volume (30 days): | 15.4M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | Dividend Payout Frequency: | Semi-Annual | |
| EPS: | 3.93 | EPS Growth: | 24.25 |
| 52 Week Low/High: | $45.05 - $120.56 | Next Earning Date: | 11-05-2025 |
| Revenue: | $49,108,936,497 | Revenue Growth: | 20.91% |
| Revenue Growth (this year): | 9.58% | Revenue Growth (next year): | 7.39% |
Latest Novo Nordisk A/S News
NVO Breaking Stock News: Dive into NVO Ticker-Specific Updates for Smart Investing
Simply Wall St.
12 hours ago
Novo Nordisk (NYSE:NVO): Is the Market Overlooking Its True Value?
MT Newswires
13 hours ago
Sector Update: Health Care Stocks Decline Pre-Bell Tuesday
MT Newswires
15 hours ago
Novo Nordisk Loses Appeal in US Court Over Medicare Drug Price Negotiation Program
Reuters Videos
16 hours ago
Novo Nordisk cuts hit production line jobs at key US plant, posts show
MT Newswires
17 hours ago
Market Chatter: Novo Nordisk Cuts Over 9,000 Jobs Globally, Including US North Carolina Facility
Insider Monkey
a day ago
What Makes Novo Nordisk A/S (NVO) a Promising and Profitable Investment in The Long Term?
Zacks
2 days ago
Zacks Value Trader Highlights: Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk
BioPharma Dive
2 days ago
Skye shares crash as obesity drug falls short in key study
Compare NVO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVO Novo Nordisk A/S - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.